Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 585-591

  Shi, Yan ^a   Qin, Rui ^a   Wang, Zhi Kuan ^a   Dai, Guang Hai ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Chemotherapy; Esophageal squamous cell carcinoma; Metastasis; Nanoparticle albumin bound paclitaxel

Indexed keywords

ALBUMIN; CISPLATIN; NANOPARTICLE; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; LEUKOPENIA; LIVER FUNCTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 84879023333     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S44406     Document Type: Article

References (41)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esopha-geal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg. 2001;234(3):360-369.
3. Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fuorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese esophageal oncology group trial. Jpn J Clin Oncol. 1992; 22(3):172-176.
4. Albertsson M, Johansson B, Friesland S, et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol. 2007;24(4):407-412.
5. Petrasch S, Welt A, Reinacher A, Graeven U, König M, Schmiegel W. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer. 1998;78(4):511-514.
6. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46.
7. Wang H, Ryu J, Gandara D, et al. A phase II study of paclitaxel, car-boplatin, and radiation with or without surgery for esophageal cancer. J Thorac Oncol. 2007;2(2):153-157.
8. Kim JY, Do YR, Park KU, et al. A multi-center phase II study of docetaxel plus cisplatin as frst-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol. 2010; 66(1):31-36.
9. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al; V325 Study Group. Phase III study of docetaxel and cisplatin plus fuorouracil compared with cisplatin and fuorouracil as frst-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-4997.
10. Overman MJ, Kazmi SM, Jhamb J, et al. Weekly docetaxel, cisplatin, and 5-fuorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 2010;116(6):1446-1453.
11. Tebbutt NC, Cummins MM, Sourjina T, et al; Australasian GastroIntestinal Trials Group. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fuorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer. 2010;102(3):475-481.
12. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremo-phor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006;17(8): 1263-1268.
13. Desai N, Trieu V, Ya o Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12(4): 1317-1324.
14. Montana M, Ducros C, Verhaeghe P, Terme T, Vanelle P, Rathelot P. Albumin-bound paclitaxel: the beneft of this new formulation in the treatment of various cancers. J Chemother. 2011;23(2):59-66.
15. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer III trial. J Clin Oncol. 2005;23(31):7794-7803.
16. Vo n Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29(34): 4548-4554.
17. Socinski MA, Manikhas GM, Stroyakovsky DL, et al. A dose fnding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as frst-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(6):852-861.
18. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-655.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92(3):205-216.
20. National Cancer Institute: Common Terminology Criteria for Adverse Events version 3.0. (CTCAE). http://ctep.cancer.gov/reporting/ctc_v30. html.
21. National Comprehensive Cancer Network Guidelines in Oncology. Esophageal cancer. Available at: http://www.nccn.org.
22. Homs MY, vd Gaast A, Siersema PD, Steyerberg E W, Kuipers EJ. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esoph-ageal junction. Cochrane Database Syst Rev. 2006;4: CD004063.
23. Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol. 2007;17(1):38-44.
24. Dreilich M, Wanders A, Brattström D, et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus. 2006;19(4):224-231.
25. Li QQ, Liu MZ, Hu YH, Liu H, He ZY, Lin HX. Defnitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus. 2010;23(3):253-259.
26. Yun T, Han JY, Lee JS, et al. Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma. BMC Cancer. 2011;11:385.
27. Takahashi H, Arimura Y, Yamashita K, et al. Phase I/II study of docetaxel/cisplatin/fuorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol. 2010; 5(1):122-128.
28. Cao W, Xu C, Lou G, et al. A phase II study of paclitaxel and nedaplatin as frst-line chemotherapy in patients with advanced esophageal cancer. Jpn J Clin Oncol. 2009;39(9):582-587.
29. Gong Y, Ren L, Zhou L, et al. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma. Cancer Chemother Pharmacol. 2009;64(2):327-333.
30. Zhang X, Shen L, Li J, Li Y, Li J, Jin M. A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus. Am J Clin Oncol. 2008;31(1):29-33.
31. Laack E, Andritzky B, Dürk H, et al. Docetaxel and cisplatin as frst-line treatment for patients with metastatic esophageal cancer: a pilot study. Onkologie. 2005;28(12):647-650.
32. Lee S, Park YH, Kim KH, et al. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma. Br J Cancer. 2010;103(6): 845-851.
33. Honda M, Miura A, Izumi Y, et al. Doxorubicin, cisplatin, and fuorouracil combination therapy for metastatic esophageal squamous cell carcinoma. Dis Esophagus. 2010;23(8):641-645.
34. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fuorouracil versus cisplatin-5-fuorouracil alone in frst-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009; 20(10):1667-1673.
35. Qin TJ, An GL, Zhao XH, et al. Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer. World J Gastroenterol. 2009;15(7):871-876.
36. Lee J, Im YH, Cho E Y, et al. A phase II study of capecitabine and cisplatin (XP) as frst-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol. 2008;62(1):77-84.
37. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041-1053.
38. Desai N P, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs. 2008;19(9):899-909.
39. Schwartzberg LS, Arena F P, Mintzer DM, Epperson AL, Walker MS. Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in frst-line treatment of patients with metastatic breast cancer. Clin Breast Cancer. 2012;12(2):87-93.
40. Link JS, Waisman JR, Nquyen B, Jacobs CI. Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. Clin Breast Cancer. 2007;7(10):779-783.
41. Mirtsching B, Cosgriff T, Harker G, Keaton M, Chidiac T, Min M. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. Clin Breast Cancer. 2011;11(2):121-128.